Cargando…
PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP
Autores principales: | Filonenko, K., Kriachok, I., Martynchyk, A., Titorenko, I., Stepanishyna, Y., Aleksyk, O., Ukianchenko, K., Pastushenko, I., Kushchevyy, Y., Novosad, O., Karnabeda, O., Diagil, I., Kozlov, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431394/ http://dx.doi.org/10.1097/01.HS9.0000851288.96490.f9 |
Ejemplares similares
-
PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
por: Novosad, O., et al.
Publicado: (2022) -
PB2283: COVID-19 (SARS-COV-2 INFECTION) IN LYMPHOMA PATIENTS
por: Tytorenko, I., et al.
Publicado: (2022) -
PB2125: VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN PATIENTS WITH PRIMARY MULTIPLE MYELOMA (MM): HIGHLIGHTING STRATEGIES THAT ACTUALLY WORK.
por: Novosad, Olga, et al.
Publicado: (2023) -
PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022) -
PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)